8-K: Rallybio Merger Closing Nears, Special Cash Distribution Details

Rallybio Corporation anticipates its merger with Avenzo Therapeutics to close on November 20, 2026, alongside detailed procedures for a $13.90 per share special cash distribution and Nasdaq listing approval.

Summary

• Rallybio Corporation expects the merger with Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc. to close on November 20, 2026, following the satisfaction of closing conditions.
• The company received Nasdaq approval to list its common stock on the Nasdaq Capital Market in connection with the merger.
• A special cash distribution of $13.90 per share will be paid to stockholders and pre-funded warrant holders of record as of November 5, 2026.
• The actual distribution of the cash is expected to commence on November 30, 2026, with payments to stockholders within a few days thereafter.
• Due to the distribution amount exceeding 25% of the stock price, Nasdaq has implemented a 'due bill' period from November 5, 2026, through November 20, 2026, requiring sellers to deliver the distribution to buyers.
• A reverse stock split is expected to take effect on November 20, 2026, at 4:01 p.m. Eastern Time.
• Contingent value rights distribution is expected on November 23, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily focused on procedural updates for a merger and a significant cash distribution, with the Nasdaq listing approval being a key positive milestone.

Positives

• Merger expected to close on November 20, 2026, indicating progress towards strategic goals.
• Nasdaq approval received for listing common stock on the Nasdaq Capital Market, a crucial step for public trading.
• A substantial special cash distribution of $13.90 per share is being made to stockholders and warrant holders.
• The reverse stock split is proceeding as planned, potentially to meet listing requirements or improve stock price perception.

Negatives

• The 'due bill' procedure for the cash distribution can create complexity for traders and requires careful consultation with brokers.
• The reverse stock split's effectiveness in sustaining a higher trading price is not guaranteed, as noted in forward-looking statements.

Risks

• The merger may be delayed or not completed if closing conditions, including Nasdaq listing approvals, are not met or waived.
• Events or circumstances could lead to the termination of the Merger Agreement.
• Delays in implementing the reverse stock split or commencing split-adjusted trading are possible.
• The reverse stock split may not result in a sustained increase in the trading price of common stock or ensure compliance with Nasdaq listing requirements.
• Risks associated with the development and commercialization of product candidates remain.

Future Outlook

The company anticipates the merger to close on November 20, 2026, with the cash distribution expected to commence on November 30, 2026. A reverse stock split is set for November 20, 2026, and contingent value rights are expected to be distributed on November 23, 2026. Forward-looking statements highlight potential risks related to merger completion, reverse stock split effectiveness, and product development.

Management Comments

• The Company has no obligations for either the amount of the due bill or the processing of the due bill.
• Buyers and sellers of the Company's common stock should consult with their broker before trading to ensure they understand the effect of Nasdaq's due bill procedures.

Industry Context

StockSavvy.ai notes that the merger and significant cash distribution, coupled with Nasdaq listing approval, are common strategic maneuvers for biotechnology companies aiming to enhance shareholder value and meet listing requirements during periods of consolidation or transition.

Comparison to Industry Standards

• The $13.90 per share special cash distribution is a significant payout, exceeding 25% of the stock price, which is a notable event often seen in biotech or pharma when a company is being acquired or undergoing a major restructuring.
• The implementation of a 'due bill' period is a standard Nasdaq procedure for large dividend distributions to ensure fairness between buyers and sellers around the record date.
• The reverse stock split is a common tool used by companies, particularly those in the biotech sector, to increase their per-share stock price to meet exchange minimums or improve marketability, though its long-term effectiveness varies.

Stakeholder Impact

• Shareholders and pre-funded warrant holders will receive a significant cash distribution of $13.90 per share.
• Shareholders who purchase stock during the 'due bill' period will be entitled to the cash distribution.
• Shareholders who sell stock during the 'due bill' period will not be entitled to the cash distribution.
• Investors need to consult brokers regarding the implications of the 'due bill' procedures.
• The reverse stock split may impact the perception and trading liquidity of the common stock.

Next Steps

• Closing of the merger with Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc. on November 20, 2026.
• Distribution of the special cash dividend commencing November 30, 2026.
• Distribution of contingent value rights on November 23, 2026.
• Trading on a split-adjusted basis following the reverse stock split effective November 20, 2026.

Key Dates

Recommendation

The filing confirms expected progress on the merger and a significant cash distribution, which are positive developments. However, the inherent risks associated with merger completion, the effectiveness of the reverse stock split, and ongoing product development, coupled with the complexity of the due bill procedures, warrant a cautious 'hold' stance until further clarity emerges post-merger and distribution.

Keywords

Merger Agreement, Special Cash Distribution, Nasdaq Listing, Due Bill, Reverse Stock Split, Contingent Value Rights, Avenzo Therapeutics